Imaprelimab (powder)
Imaprelimab (powder) is a humanized IgG1κ anti-CD146 antibody. Imaprelimab (powder) exerts anti-angiogenic effects on brain metastasis of lung cancer in animal models. Imaprelimab (powder) can be used in studies related to brain metastasis of non-small cell lung cancer.
For research use only. We do not sell to patients.
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Human IgG1 kappa
Human
Imaprelimab (10 mg/kg; i.p.; every two days; 3 weeks) inhibits intracranial non-small cell lung carcinoma brain metastasis growth and angiogenesis more potently than Bevacizumab (HY-P9906) in mice[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB-c-nu (female, 4-6 weeks old)[1]
-
Dosage:10 mg/kg
-
Administration:i.p.; every two days; 21 days
-
Result:Significantly suppressed subcutaneous tumor growth compared with vehicle control and bevacizumab.
Reduced final tumor weight and lower tumor vascular density (measured via MRI F-value).
-
Animal Model:BALB-c-nu (female, 4-6 weeks old)[1]
-
Dosage:10 mg/kg
-
Administration:i.p.; every two days; 3 weeks
-
Result:Significantly suppressed intracranial tumor growth (measured via bioluminescence photo flux) compared with vehicle control and bevacizumab.
Reduced intracranial tumor vascular density (measured by CD31-positive vessel count per field) more effectively than bevacizumab.
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
IgG1-kappa
ELISA, FACS, Functional assay
Chemical Information
-
SMILES
[Imaprelimab (powder)]
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Imaprelimab (powder) Related Classifications
Cat. No.: HY-P99658A
Powered by Bioz
- Imaprelimab (powder)
- Transmembrane Glycoprotein
- non-small cell lung carcinoma-derived brain metastasis
- anti-angiogenic agent
- CD146
- animal models
- lung cancer brain metastasis
- intracranial non-small cell lung carcinoma brain metastasis
- bevacizumab
- subcutaneous non-small cell lung carcinoma brain metastasis mouse model
- Inhibitor
- inhibitor
- inhibit